RPE Cell Regeneration Compounds for AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) and related retinal pigment epithelium (RPE) diseases, particularly dry AMD and geographic atrophy, lack effective solutions for reversing RPE cell damage and restoring vision, with existing therapies only managing symptoms or slowing disease progression.
Innovation Solution
Development of compounds that stimulate the pigmentation and growth of mammalian RPE cells, allowing for controlled repair and regeneration of the retina, thereby preventing vision loss and potentially restoring vision by promoting the proliferation and differentiation of healthy RPE cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for dry AMD and geographic atrophy are used, then disease progression is slowed or symptoms are managed, but RPE cell damage cannot be reversed and vision loss cannot be restored
Solution Approach 1:
Instead of attempting to prevent RPE cell death through complement inhibition (current approach), the invention inverts the strategy by directly stimulating the proliferation and differentiation of RPE cells to regenerate lost tissue. This fundamental reversal from protection to regeneration enables actual restoration of damaged RPE layers and potential recovery of vision, rather than merely slowing disease progression.
2Reliability
If transplantation of stem cells or mature RPE cells is performed, then RPE cell replacement is achieved, but the procedure is complex and invasive
Solution Approach 1:
The invention enables the body's own RPE cells to serve themselves by stimulating endogenous proliferation and differentiation. Rather than requiring external transplantation procedures, the treatment activates the patient's own cellular regenerative capacity, allowing RPE cells to self-replace damaged tissue through controlled proliferation and differentiation responses to the administered compounds.
3Object-affected harmful factors
If anti-VEGF agents are used for wet AMD, then neovascularization is controlled, but RPE cell loss and geographic atrophy are not addressed
Solution Approach 1:
The invention segments the treatment approach by separating the management of neovascularization (handled by anti-VEGF agents) from the regeneration of RPE tissue (handled by the new compounds). This segmentation allows simultaneous addressing of both pathological processes - controlling harmful neovascularization while promoting beneficial RPE cell proliferation and differentiation to repair geographic atrophy.
Data Source
AI summary
A method of treating and/or preventing a disease involving the retinal pigment epithelium, including administering the compound of the formula (I)or pharmaceutically acceptable salt, racemic mixture, corresponding enantiomer or corresponding diastereomer thereof, wherein: X is NH or O, R11, R12 and R13 are hydrogen, fluoro, chloro, trifluoromethyl, methyl or difluoromethoxy, A is a residue of formula (II), (III), (IV), (V), (VI), (VII) or (VIII)wherein, “*” denotes the point of attachment to the remainder of the molecule, R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V, R2VI, R3VI, R4VI and R5VI are hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, fluoro, chloro, bromo, methoxy, ethoxy, propoxy, trifluoromethyl, 2,2,2-trifluoroethyl or difluoromethoxy and R6 is hydrogen, a linear or branched alkyl having 1 to 3 carbon atoms, trifluoromethyl, or 2,2,2-trifluoroethyl.